Invitation | Weiboxin Biotechnology Invites You to the 11th China Veterinary Congress!

The 11th China Veterinary Congress will be held from August 23 to 25, 2024, at the Wuhan Optics Valley Science and Technology Convention Center, concurrently with the 2024 Animal Husbandry and Veterinary Supplies Exhibition. This year’s congress is themed “Digital Leadership, Innovation-Driven Development, Green Transformation, and the Cultivation of New Quality Productive Forces in Animal Husbandry and Veterinary Medicine.” It will feature specialized sessions on swine, poultry, cattle and sheep, pets, and traditional Chinese veterinary medicine, among others. Leaders from relevant industry regulatory authorities and domestic and international experts will be invited to interpret national and industry policies, analyze the economic outlook for the livestock sector, present the current epidemiological situation of animal diseases, share domestic and international best practices in healthy farming management, discuss disease prevention and control strategies, explore future trends in livestock production, and highlight advances in clinical diagnostic and therapeutic techniques as well as new breakthroughs in pharmaceutical research and development. On that occasion, Weiboxin, as a manufacturer of diagnostic reagents for animal epidemics, Simultaneously possess Molecular Diagnostic Products (Class B) and The GMP production line for immunology-based diagnostic products (Class B) will deliver a range of flagship products and solutions. We cordially invite all partners to visit, engage in exchanges and learning, and jointly explore opportunities for collaboration and development.

At this conference, Guangzhou Weiboxin will bring its certified products: the African Swine Fever Virus Fluorescent PCR Detection Kit (Veterinary Drug Registration No. 191438923), the Porcine Reproductive and Respiratory Syndrome Virus ELISA Antibody Detection Kit (Veterinary Drug Registration No. 191438213), and the Classical Swine Fever Virus Blocking ELISA Antibody Detection Kit (Veterinary Drug Registration No. 191438875), as well as Other Core Bestsellers We look forward to welcoming our valued customers to Booth D26 for交流 and guidance!

When looking for animal disease testing reagents, choose the Weiboxin brand.

Be aware of Weiboxin Bio All products of!

Official consultation phone numbers: 020-66377266 / 135 3988 6748, Ms. Dai

Guangzhou Weiboxin Biotechnology Co., Ltd. is located in the national-level innovation park—Guangzhou Science City—and is a provincial-level “Little Giant” high-tech enterprise specializing in the forward R&D, manufacturing, sales, and technical services of diagnostic reagents for animal epidemics. The company is also recognized as a “Contract-Honoring and Credit-Keeping Enterprise” in Guangdong Province and a provincial demonstration unit for intellectual property, as well as a industry–university–research collaboration base of Guangdong Food and Drug Vocational College and an executive director unit of the Veterinary Diagnostic and Biological Products Committee of the Guangdong Society of Animal Husbandry and Veterinary Medicine. It has been designated by multiple research institutes, including the Entrepreneurship College of Jinan University in Guangdong Province, as an innovative enterprise with strong growth potential. Furthermore, it has been rated as a “Specialized, Refined, Distinctive, and Innovative” enterprise at both municipal and provincial levels, receiving awards such as “Most Investment-Valuable Enterprise” and “Annual African Swine Fever and Pig Disease Testing Service Provider.” The company has also obtained veterinary drug product approval numbers from the Ministry of Agriculture and Rural Affairs: Veterinary Drug Registration No. 191438923 (African Swine Fever Virus Fluorescent PCR Diagnostic Kit), Veterinary Drug Registration No. 191438213 (Reproductive and Respiratory Syndrome Virus ELISA Antibody Detection Kit), and Veterinary Drug Registration No. 191438875 (Classical Swine Fever Virus Blocking ELISA Antibody Detection Kit). In the 11th China Innovation and Entrepreneurship Competition, the company won the Excellence Award in the Growth Category of the Biopharmaceutical Industry; in the Nanotechnology Industry Technology Competition under the same event, it secured the Provincial Second Prize in the Growth Category; and in the National Finals of the Nanotechnology Industry Technology Innovation Special Competition within the China Innovation and Entrepreneurship Competition, it was awarded the National Third Prize in the Growth Category. The company has consecutively received the A-Level Tax Credit Honor Certificate, the Four-Star Trademark Brand Certification, and the Two-Integration Management System Assessment Certificate each year, as well as ISO 9001 International Quality Management System Certification and ISO 14001 International Environmental Management System Certification, and has also obtained GMP certification from the Ministry of Agriculture. Since its establishment, the company has been granted a total of 24 patents, including 5 invention patents, 15 utility model patents, and 4 design patents, in addition to more than ten registered trademarks.

The company boasts robust technical capabilities and a team of world-class professionals, including dozens of masters, doctors, and returnees who studied abroad, as well as numerous senior-title technical experts. Currently, the company’s primary focus is on the research and development of molecular diagnostic reagents. Its core R&D team has developed more than 600 products spanning molecular diagnostics and immunoassays, including public-health–oriented fluorescent PCR test kits, animal disease–control–oriented fluorescent PCR test kits, clinical and research–grade fluorescent quantitative PCR kits, and transgenic identification test kits (ZL2006). The company has also established a nationwide distribution network covering more than ten major cities, such as Beijing, Shanghai, Hangzhou, Nanjing, Xi’an, Chongqing, Lanzhou, Zhengzhou, and Qingdao.

Looking ahead, Weiboxin will remain steadfast in its commitment to continuously enhance product quality and service standards. Leveraging a rapid and efficient research platform and abundant biomedical resources, we will conduct extensive and in-depth R&D and scientific research in the biomedical field, thereby contributing to human health and advancing life sciences. Quality is our lifeline; innovation is our soul. Upholding this guiding principle, we will relentlessly strive to become the premier supplier of rapid diagnostic reagents and instruments.